Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vcanbio Cell & Gene Engineering Corp., Ltd (600645.SS)
Tianjin, CN
Vcanbio Cell & Gene Engineering Corp., Ltd, established in 1992 and headquartered in Tianjin, China, primarily focuses on providing cell preparation and cryopreservation services across the People's Republic of China. The company's offerings include the handling and storage of a diverse array of stem cells, such as hematopoietic stem cells derived from umbilical cord blood, umbilical cord mesenchymal stem cells, placental sub-totipotent stem cells, adipose stem cells, and dental stem cells, alongside immune cells. Beyond its core cell banking operations, Vcanbio delivers a spectrum of genetic testing services. These include non-invasive prenatal screening, pharmacogenomic testing for safe medication guidance in both adults and children, and analyses for disease genetics and susceptibility. Additionally, the company supplies essential raw materials for in vitro diagnostics, specifically monoclonal and polyclonal antibodies. Vcanbio is also actively involved in the research, development, manufacturing, and commercialization of various biological products, including genes, proteins, and antibodies, as well as pharmaceutical intermediates, experimental synthetic agents, in vitro diagnostic reagents, and medical devices.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.15% | -5.24% | -23.08% | -27.43% | -29.95% | -21.03% | -11.63% | +17.13% | -22.78% | -47.49% | +379.14% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-8.2% Q1'26: -9.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+13.6% Q1'26: -16.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+15.4% ★ Q1'26: +6.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+13.5% ★ Q1'26: +11.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+5.6% ★ Q1'26: +4.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.2% ★ Q1'26: +3.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.20× ★ Q1'26: 0.19× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
708.99M
est: 778.00M (-8.9%)
|
837.90M
est: 1.28B (-34.5%)
|
1.32B
est: 1.48B (-10.9%)
|
1.32B
est: 778.00M (+69.7%)
|
1.39B
est: 1.28B (+8.4%)
|
1.32B
est: 1.48B (-11.1%)
|
1.54B
est: 1.60B (-4.0%)
|
1.55B
est: 1.95B (-20.1%)
|
1.59B
est: 1.93B (-17.6%)
|
1.59B
est: 1.68B (-5.7%)
|
1.45B
est: 1.78B (-18.2%)
|
1.88B
1.88B – 1.88B
+6.0% YoY
|
| EBITDA |
147.78M
est: 125.29M (+18.0%)
|
163.89M
est: 205.97M (-20.4%)
|
192.65M
est: 238.82M (-19.3%)
|
146.21M
est: 125.29M (+16.7%)
|
274.59M
est: 205.97M (+33.3%)
|
196.82M
est: 238.82M (-17.6%)
|
227.35M
est: 257.67M (-11.8%)
|
253.74M
est: 313.55M (-19.1%)
|
281.74M
est: 310.81M (-9.4%)
|
265.53M
est: 298.15M (-10.9%)
|
335.87M
est: 315.35M (+6.5%)
|
334.15M
334.15M – 334.15M
+6.0% YoY
|
| EBIT |
102.83M
est: 67.48M (+52.4%)
|
108.37M
est: 110.94M (-2.3%)
|
91.98M
est: 128.64M (-28.5%)
|
44.16M
est: 67.48M (-34.6%)
|
178.34M
est: 110.94M (+60.7%)
|
93.51M
est: 128.64M (-27.3%)
|
124.44M
est: 138.79M (-10.3%)
|
142.93M
est: 168.89M (-15.4%)
|
138.14M
est: 167.41M (-17.5%)
|
163.20M
est: 167.39M (-2.5%)
|
196.55M
est: 177.05M (+11.0%)
|
187.61M
187.61M – 187.61M
+6.0% YoY
|
| Net Income |
208.35M
est: 189.30M (+10.1%)
|
37.86M
est: 241.76M (-84.3%)
|
10.37M
est: 319.30M (-96.8%)
|
59.25M
est: 189.30M (-68.7%)
|
49.69M
est: 241.76M (-79.4%)
|
-126.86M
est: 319.30M (-139.7%)
|
155.32M
est: 205.27M (-24.3%)
|
112.99M
est: 287.37M (-60.7%)
|
106.45M
est: 159.65M (-33.3%)
|
100.35M
est: 136.60M (-26.5%)
|
113.83M
est: 154.81M (-26.5%)
|
177.58M
177.58M – 177.58M
+14.7% YoY
|
| SGA |
337.31M
est: 361.25M (-6.6%)
|
400.78M
est: 593.88M (-32.5%)
|
633.75M
est: 688.60M (-8.0%)
|
637.08M
est: 361.25M (+76.4%)
|
595.54M
est: 593.88M (+0.3%)
|
630.50M
est: 688.60M (-8.4%)
|
748.91M
est: 742.93M (+0.8%)
|
722.21M
est: 904.05M (-20.1%)
|
719.77M
est: 896.16M (-19.7%)
|
695.33M
est: 771.14M (-9.8%)
|
654.87M
est: 815.64M (-19.7%)
|
864.27M
864.27M – 864.27M
+6.0% YoY
|
| EPS |
0.54
est: 0.42 (+30.1%)
|
0.10
est: 0.53 (-81.1%)
|
0.03
est: 0.70 (-95.7%)
|
0.15
est: 0.42 (-63.9%)
|
0.11
est: 0.53 (-79.2%)
|
-0.27
est: 0.70 (-138.6%)
|
0.33
est: 0.45 (-26.2%)
|
0.24
est: 0.63 (-61.7%)
|
0.23
est: 0.35 (-34.3%)
|
0.22
est: 0.30 (-26.7%)
|
0.25
est: 0.34 (-26.5%)
|
0.39
0.39 – 0.39
+14.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 16.8K | 0.44% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 336.6K | 0.06% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 11.1K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 25.1K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.24M | 0.06% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 68.0K | 0.29% |
| 7 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 51.8K | 0.39% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 45.6K | 0.28% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 22.3K | 0.10% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.30M | 0.05% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hong Xiang Shi | Deputy General Manager | — | male |
| Hongqi Wang | Vice Chairman & GM | — | male |
| Huang Jiaxue | Chief Technical Quality Officer | — | — |
| Yi Qing Chen | Deputy GM, Chief Financial Officer & Secretary | — | — |
| Yu Zhang | R&D Director | — | male |
| Yueming Wang | Chief Human Resources Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600645.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
